All In Biotech

Drug Trial Radar · NCT04223856

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 886 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

886

Actual

Start

Mar 30, 2020

Primary completion

Aug 8, 2023

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Seagen Inc.
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.

Conditions

  • Urothelial Cancer

Interventions

  • Enfortumab vedotinDrug

    Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle

  • PembrolizumabDrug

    IV infusion on Day 1 of every 3-week cycle

  • CisplatinDrug

    administered as IV infusion on Day 1 of each 3-week cycle

  • CarboplatinDrug

    Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle

  • GemcitabineDrug

    IV infusion on Days 1 and 8 of every 3 week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)Time frame: From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum exposure to treatment was up to 39.2 months)
  2. Overall Survival (OS)Time frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum exposure to treatment was up to 39.2 months)

Locations

260 sites in 25 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers - Chandler

    Chandler, Arizona

  • Arizona Oncology Associates PD - HOPE

    Tucson, Arizona

  • Providence St Joseph Medical Center

    Burbank, California

  • City of Hope National Medical Center

    Duarte, California

  • University of California Los Angeles Medical Center

    Los Angeles, California

  • University of California Irvine - Newport

    Orange, California

  • Rocky Mountain Cancer Centers - Aurora

    Aurora, Colorado

  • University of Colorado Hospital / University of Colorado

    Aurora, Colorado

  • Cancer Centers of Colorado - Denver

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Eastern CT Hematology and Oncology Associates

    Norwich, Connecticut

  • Lombardi Cancer Center / Georgetown University Medical Center

    Washington D.C., District of Columbia

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Winship Cancer Institute / Emory University School of Medicine

    Atlanta, Georgia

  • Georgia Cancer Specialists / Northside Hospital Cancer Institute

    Marietta, Georgia

  • Louisiana State University/ East Jefferson General Hospital

    Metairie, Louisiana

  • Maine Health Cancer Care

    Biddeford, Maine

  • Johns Hopkins Medical Center

    Baltimore, Maryland

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • New Mexico Cancer Center

    Albuquerque, New Mexico

  • New York University (NYU) Cancer Institute

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Vidant Medical Center

    Greenville, North Carolina

  • The Cleveland Clinic

    Cleveland, Ohio

  • Toledo Clinic Cancer Center

    Toledo, Ohio

  • Hillman Cancer Center / University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Saint Francis Hospital / Bon Secours - South Carolina

    Greenville, South Carolina

  • West Cancer Center & Research Institute

    Germantown, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • UT Health East Texas Hope Cancer Center

    Tyler, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Seattle Cancer Care Alliance / University of Washington

    Seattle, Washington

  • Site AR54008

    Buenos Aire, Argentina

  • Site AR54011

    CABA, Argentina

  • Site AR54005

    Córdoba, Argentina

  • Site AR54006

    La Rioja, Argentina

  • Site AR54004

    Mendoza, Argentina

  • Site AR54001

    Rosario, Argentina

Showing 40 of 260 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.